Format

Send to

Choose Destination
Semin Cancer Biol. 1999 Apr;9(2):125-38.

The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy.

Author information

1
Department of Pathology and Laboratory Medicine, Albany Medical College, 47 New Scotland Avenue, Albany, MA, NY 12208, USA.

Abstract

The HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor. HER-2/neu has been widely studied in breast cancer. The potential value of HER-2/neu status for the prediction of disease outcome and response to therapy in breast cancer is presented in the light of a series of recently published studies showing a range of impact on the outcome of patients treated with hormonal, cytotoxic and radiation therapies. This review includes the application of serum-based HER-2/neu testing and the use of antibody-based therapies directed against the HER-2/neu protein and their potential to become a new modality for breast cancer treatment.

PMID:
10202134
DOI:
10.1006/scbi.1998.0083
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center